

ment of obesity in these patients. It has been estimated that up to 80% to 90% of patients with OSA are undiagnosed,<sup>8</sup> and weight reduction as a treatment of OSA is underrated by many clinicians. There are no national programs for screening OSA or preventing its progression. Thus, there is a definite need for larger, well-controlled trials on the effects of different lifestyle programs among patients with OSA to determine the overall efficacy and long-term success, before large-scale programs may be implemented in clinical settings, as have been done for prevention of type 2 diabetes mellitus, for example.

Henri Tuomilehto, MD, PhD  
Juha Seppä, MD, PhD  
Matti Uusitupa, MD, PhD  
Jaakko Tuomilehto, MD, MA, PhD  
Helena Gylling, MD, PhD  
for the Kuopio Sleep Apnea Group

**Published Online:** April 15, 2013. doi:10.1001/jamainternmed.2013.389

**Author Affiliations:** Oivauni Sleep Clinic, Kuopio, Finland (Dr H. Tuomilehto); Department of Otorhinolaryngology (Dr Seppä) and Clinical Research Center (Drs Uusitupa and Gylling), Kuopio University Hospital, Kuopio, Finland; Institute of Clinical Medicine (Dr Seppä) and Department of Clinical Nutrition, Institute of Public Health and Clinical Nutrition, (Drs Uusitupa and Gylling), University of Eastern Finland, Kuopio; Center for Vascular Prevention, Danube-University Krems, Krems, Austria (Dr J. Tuomilehto); South Ostrobothnia Central Hospital, Seinäjoki, Finland (Dr J. Tuomilehto); and Department of Medicine, Division of Internal Medicine, University of Helsinki, Helsinki, Finland (Dr Gylling).

**Correspondence:** Dr H. Tuomilehto, Oivauni Sleep Clinic, Puijonkatu 12 B, 70100 Kuopio, Finland (henri.tuomilehto@oivauni.fi).

**Author Contributions:** Dr H. Tuomilehto had full access to all data in the study and had final responsibility to submit the report for publication. *Study concept and design:* All authors. *Acquisition of data:* H. Tuomilehto, Seppä, and Gylling. *Analysis and interpretation of data:* All authors. *Drafting of the manuscript:* H. Tuomilehto, Seppä, Uusitupa, and Gylling. *Critical revision of the manuscript for important intellectual content:* H. Tuomilehto, Seppä, Uusitupa, J. Tuomilehto, and Gylling. *Statistical analysis:* H. Tuomilehto, Seppä, and J. Tuomilehto. *Obtained funding:* H. Tuomilehto. *Administrative, technical, and material support:* H. Tuomilehto, Uusitupa, and Gylling. *Study supervision:* All authors.

**Kuopio Sleep Apnea Group:** Grigori Smirnov, MD, PhD, Johanna Sahlman, MD, PhD, Matti Pukkila, MD, PhD, Markku Peltonen, PhD, Tarja Martikainen, MSc, Jouko Kokkarinen, MD, PhD, Jukka Randell, MD, PhD, Esko Vanninen, MD, PhD, Taina Poutiainen, Tomi Laitinen, MD, PhD, Tiina Lyra-Laitinen, PhD, Ritva Vanninen, MD, PhD, Kari Punnonen, MD, PhD, Aki Ikonen, MD, Riitta Pahkala, DD, PhD, Erkki Soini, BSc, and Janne Martikainen.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** The study was funded by the Hospital District of Northern Savo. Kuopio University Hospi-

tal, the Juho Vainio Foundation, Yrjö Jahnsson Foundation, Paulo Foundation, Finnish Cultural Foundation, Finnish Research Foundation of Otolaryngology, Finnish Medical Foundation, Respiratory Foundation, and the Finnish Anti-Tuberculosis Foundation have supported the study with grants.

**Role of the Sponsors:** The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

**Online-Only Material:** The eFigure and eTables are available at <http://www.jamainternalmed.com>.

**Additional Contributions:** Markku Peltonen, MD, assisted with the statistical analyses. Grigori Smirnov, MD, PhD, Matti Pukkila, MD, PhD, Esko Vanninen, MD, PhD, Jouko Kokkarinen, MD, PhD, Jukka Randell, MD, PhD, Johanna Sahlman, MD, PhD, and Tarja Martikainen, MSc, contributed to clinical work related to the study. They also participated in interpreting the results and in editing of the manuscript. All group members approved the current version of the manuscript. The other members of Kuopio Sleep Apnea Group are cordially acknowledged.

**Trial Registration:** clinicaltrials.gov Identifier: NCT00486746

1. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med.* 2009;6(8):e1000132.
2. Marin JM, Carrizo SJ, Vicente E, Agustí AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet.* 2005;365(9464):1046-1053.
3. Berger G, Berger R, Oksenberg A. Progression of snoring and obstructive sleep apnoea: the role of increasing weight and time. *Eur Respir J.* 2009;33(2):338-345.
4. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. *JAMA.* 2004;291(16):2013-2016.
5. Tuomilehto HP, Seppä JM, Partinen MM, et al; Kuopio Sleep Apnea Group. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. *Am J Respir Crit Care Med.* 2009;179(4):320-327.
6. Tuomilehto H, Gylling H, Peltonen M, et al; Kuopio Sleep Apnea Group. Sustained improvement in mild obstructive sleep apnea after a diet- and physical activity-based lifestyle intervention: postinterventional follow-up. *Am J Clin Nutr.* 2010;92(4):688-696.
7. American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research: the report of an American Academy of Sleep Medicine Task Force. *Sleep.* 1999;22(5):667-689.
8. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. *Am J Respir Crit Care Med.* 2002;165(9):1217-1239.

## LESS IS MORE

### Investigation Momentum: The Relentless Pursuit to Resolve Uncertainty

**D**ebate regarding the prostate-specific antigen (PSA) screening test centers around test reliability and whether screening reduces mortality.<sup>1-3</sup> We consider yet another potential downside to the widespread use of unreliable screening tests: the downstream effect of receiving inconclusive or ambiguous

*For editorial comment  
see page 847*

results. When receiving information from screening tests, we usually want to know whether the result is a “yes” or a “no.” Receiving an inconclusive result amounts to a “don’t

**Table. Characteristics of Survey Respondents by Assigned Prostate-Specific Antigen (PSA) Test Result Group**

Characteristic	Respondents, No. (%) (n = 727) <sup>a</sup>				P Value
	No PSA Test (n = 163)	Inconclusive PSA Level (n = 185)	Elevated PSA Level (n = 182)	Normal PSA Level (n = 197)	
Age, y					
40-50	28 (17.2)	33 (17.8)	34 (18.7)	26 (13.2)	.51 <sup>b</sup>
51-60	49 (30.1)	64 (34.6)	53 (29.1)	62 (31.5)	
61-70	51 (31.3)	54 (29.2)	51 (28.0)	67 (34.0)	
71-75	15 (9.2)	16 (8.6)	21 (11.5)	19 (9.6)	
Unanswered	20 (12.3)	18 (9.7)	23 (12.6)	23 (11.7)	
Perceived lifetime risk of prostate cancer, %					
0-25	109 (66.9)	130 (70.3)	117 (64.3)	122 (61.9)	.34 <sup>b</sup>
26-50	26 (16.0)	35 (18.9)	36 (19.8)	49 (24.9)	
51-75	19 (11.7)	13 (7.0)	12 (6.6)	21 (10.7)	
76-100	8 (4.9)	6 (3.2)	14 (7.7)	5 (2.5)	
Unanswered	1 (0.6)	1 (0.5)	3 (1.6)	0	
Previous screening examinations					
PSA and DRE	83 (50.9)	105 (56.8)	93 (51.1)	112 (56.9)	.90 <sup>c</sup>
PSA only	31 (19.0)	23 (12.4)	31 (17.0)	33 (16.8)	
DRE only	18 (11.0)	20 (10.8)	20 (11.0)	17 (8.6)	
Neither PSA nor DRE	26 (16.0)	34 (18.4)	32 (17.6)	30 (15.2)	
I don't know	5 (3.1)	3 (1.6)	6 (3.3)	5 (2.5)	
Race/ethnicity					
White	144 (88.3)	167 (90.3)	165 (90.7)	178 (90.4)	.90 <sup>c</sup>
Other races and ethnicities	18 (11.1)	17 (9.2)	16 (8.7)	19 (9.6)	
Unanswered	1 (0.6)	1 (0.5)	1 (0.6)	0	
History of prostate cancer in father or brothers					
Yes	30 (18.4)	24 (13.0)	22 (12.1)	30 (15.2)	.72 <sup>c</sup>
No	124 (76.1)	149 (80.5)	148 (81.3)	157 (79.7)	
I don't know	9 (5.5)	12 (6.5)	12 (6.6)	10 (5.1)	
History of breast cancer in mother or sisters					
Yes	26 (16.0)	30 (16.2)	25 (13.7)	37 (18.8)	.81 <sup>c</sup>
No	133 (81.6)	152 (82.2)	151 (83.0)	154 (78.2)	
I don't know	4 (2.5)	3 (1.6)	6 (3.3)	6 (3.0)	
Would you undergo a prostate biopsy?					
Yes	40 (24.5)	73 (39.5)	112 (61.5)	25 (12.7)	<.001 <sup>c</sup>
No	123 (75.5)	112 (60.5)	70 (38.5)	172 (87.3)	
How certain are you in whether or not you would receive a biopsy?					
-100 to -61 (most certain would not)	55 (33.7)	43 (23.2)	22 (12.1)	99 (50.3)	<.001 <sup>b</sup>
-60 to -21	27 (16.6)	43 (23.2)	29 (15.9)	44 (22.3)	
-20 to 20 (most uncertain)	45 (27.6)	30 (16.2)	23 (12.6)	31 (15.7)	
21 to 60	20 (12.3)	31 (16.8)	34 (18.7)	12 (6.1)	
61 to 100 (most certain would)	16 (9.8)	38 (20.5)	74 (40.7)	11 (5.6)	

Abbreviation: DRE, digital rectal examination.

<sup>a</sup>Participants were recruited from a sample of golf players. The study protocol was approved by the institutional review board of Duke University, Durham, North Carolina, and included a waiver for written consent. In 2012, we e-mailed 14 692 men and stopped recruiting once we received 1003 responses. We excluded 276 participants who completed the survey in less than 1.5 minutes, were inconsistent responders, or had previously received a diagnosis of prostate cancer, leaving a resulting sample size of 727 for analysis. A likelihood ratio (LR) test revealed that these excluded participants were not unequally distributed across the 4 conditions: LR = 2.45; P = .48.

<sup>b</sup>Calculated by means of analysis of variance test.

<sup>c</sup>Calculated by means of  $\chi^2$  test.

know”; this situation should have a level of uncertainty regarding the diagnosis similar to that of not conducting the test at all. Yet, we propose that the psychological uncertainty experienced after an inconclusive test result can lead to *investigation momentum*: additional, and potentially excessive, diagnostic testing. In contrast, not conducting the unreliable test would result in no further action. To investigate this, we evaluated whether receiving an inconclusive result from an unreliable test (the PSA screening), compared with undergoing no test, motivated more individuals to undertake an additional, more invasive and costly, test (a prostate biopsy).

**Methods.** We recruited 727 men aged between 40 and 75 years to an online survey through e-mail solicitation (data

were subsequently collected and analyzed anonymously). Participants received information regarding prostate cancer and answered some background questions (see **Table**). They were randomized to 1 of 4 conditions. In the first condition, “no PSA,” participants were given information about the risks and benefits of prostate biopsies and asked whether they would have a biopsy (yes or no) and their certainty, ranging from -100 (most certain they would not undergo biopsy) to +100 (most certain they would). In the other 3 conditions, participants were given information about PSA tests, as well as prostate biopsies, and were then presented with a scenario that asked them to imagine that they had just received their PSA test result at 1 of 3 PSA levels: normal, elevated, or inconclusive—the latter result stated “this result provides no information about whether

or not you have cancer.” After getting the information about the PSA test and a particular outcome, participants were asked to indicate whether, under these conditions, they would undergo a biopsy and their level of certainty in that decision.

We conducted 2-sided  $\chi^2$  tests and analyses of variance with planned contrasts to examine differences between the 4 conditions.  $P < .05$  was considered statistically significant.

**Results.** There were no significant differences among the 4 conditions in participant age, believed likelihood of developing prostate cancer, previous screening examinations, race, and family history of prostate or breast cancer (Table). As hypothesized, significantly more men indicated that they would undergo a prostate biopsy if they received an inconclusive PSA test result (40%) than if they had no PSA test (25%;  $\chi^2 = 8.80$ ;  $P = .003$ ). Men in the elevated and normal PSA level conditions also responded significantly differently: Those assigned an elevated PSA test result were more likely to state that they would undergo a biopsy (62%) compared with those who had no PSA test ( $\chi^2 = 47.76$ ;  $P < .001$ ) and compared with those assigned an inconclusive PSA test result ( $\chi^2 = 17.89$ ;  $P < .001$ ) (although 38% of men with an elevated PSA test result still would not opt for a biopsy). Those assigned a normal PSA test result were less likely to state that they would undergo a biopsy (13%) compared with those who had no PSA test ( $\chi^2 = 8.47$ ;  $P = .004$ ) (demonstrating some, but not total, reassurance from receiving a normal PSA test result)<sup>4</sup> and compared with those assigned an inconclusive PSA test result ( $\chi^2 = 35.85$ ;  $P < .001$ ) and those assigned an elevated PSA test result ( $\chi^2 = 97.80$ ;  $P < .001$ ). Similar results, and significance, were obtained with participants' certainty ratings (Table).

**Comment.** These results are likely not confined to the PSA test and provide evidence that an inconclusive test result sparks investigation momentum. When tests give no diagnostic information, rationally, from an information perspective, it should be equivalent to never having had the test for the purpose of future decision making. Yet, we find that more men would opt to undergo the more invasive biopsy after receiving a meaningless test result than when they have no result at all. This has financial and clinical implications owing to the cost and invasive nature of further investigations. Furthermore, such a tendency is likely to have an impact not only on those physicians who incorporate patients' preferences into medical decision making<sup>5</sup> but on all physicians, because they are vulnerable to the same psychological processes that encourage patients to resolve ambiguity.<sup>6</sup> These results suggest that the ubiquitous use of simple but unreliable screening tests may lead to consequences beyond the initial cost and patient anxiety of inconclusive results; they could also lead to investigation momentum. Furthermore, it is possible that just ordering a test may lead to a commitment to pursue and find abnormalities.<sup>7</sup> As we have also seen previously, sometimes “less is more” when it comes to health care procedures with incremental benefit but definite risks such as imaging for low back pain (a symptom likely to generate investiga-

tion momentum).<sup>8</sup> These findings need to be replicated in broader populations and clinical settings to allow us to better understand how ambiguous information affects medical decision making.

Sunita Sah, MD, MBA, PhD  
Pierre Elias, BA  
Dan Ariely, PhD

**Published Online:** April 15, 2013. doi:10.1001/jamainternmed.2013.401

**Author Affiliations:** McDonough School of Business, Georgetown University, Washington, DC (Dr Sah); Ethics Center, Harvard University, Cambridge, Massachusetts (Dr Sah); and Fuqua School of Business, Duke University, Durham, North Carolina (Dr Ariely). Mr Elias is a medical student at Duke University School of Medicine, Durham.

**Correspondence:** Dr Sah, Georgetown University, McDonough School of Business, 37th and O Street, Rafik B. Hariri Bldg, Washington, DC 20057 (ss3250@georgetown.edu).

**Author Contributions:** Dr Sah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* All authors. *Acquisition of data:* Elias. *Analysis and interpretation of data:* Sah and Elias. *Drafting of the manuscript:* Sah. *Critical revision of the manuscript for important intellectual content:* All authors. *Statistical analysis:* Sah and Elias. *Obtained funding:* Ariely. *Study supervision:* Sah and Ariely.

**Conflict of Interest Disclosures:** None reported.

1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(2):120-134.
2. Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst.* 2010;102(9):605-613.
3. Chou R, LeFevre ML. Prostate cancer screening—the evidence, the recommendations, and the clinical implications. *JAMA.* 2011;306(24):2721-2722.
4. Detsky AS. A piece of my mind: underestimating the value of reassurance. *JAMA.* 2012;307(10):1035-1036.
5. McNaughton-Collins MF, Barry MJ. One man at a time—resolving the PSA controversy. *N Engl J Med.* 2011;365(21):1951-1953.
6. Ellsberg D. Risk, ambiguity, and the savage axioms. *QJ Econ.* 1961;75(4):643-669.
7. Staw BM. The escalation of commitment to a course of action. *Acad Manage Rev.* 1981;6(4):577-587.
8. Srinivas SV, Deyo RA, Berger ZD. Application of “less is more” to low back pain. *Arch Intern Med.* 2012;172(13):1016-1020.

## COMMENTS AND OPINIONS

### Internists: Who Are We—And Where Are We Going?

*Nothing will sustain you more potently than the power to recognize in your humdrum routine, as perhaps it may be thought, the true poetry of life—the poetry of the commonplace, of the ordinary man, of the plain, toil-worn woman, with their lives and their joys, their sorrows and their griefs.*

William Osler<sup>1</sup>

When I began my internal medicine practice, internists were experts in diagnosis and medical treatment and consultants, who cared for the sickest of the sick.